Epistem plc, the UK biotechnology and personalized medicine company, has announced that their Contract Research Division’s histology and immunohistochemistry (IHC) laboratories have been awarded Good Clinical Laboratory Practise (GCLP) accreditation status.
The Contract Research Division provides solutions to support preclinical testing and clinical drug development programs within pharmaceutical and biotechnology organizations, providing valuable information on drug efficacy, target identification and protein biomarkers.
The team provide a specialized histology and IHC serice in UK Human Tissue Authority accredited laboratories, specializing in the development of novel methods for protein detection and localization. Epistem develops antibody novel labeling protocols and provides quality controlled datra sets and publication quality images, complemented by use of the GLP compliant Ariol and Aperio PRECISION image analysis platforms.
GCLP status demonstrates that the Contract Research Division operates to standard set by the British Assocation of Research Quality Assurance that assures the reliability, quality and integrity of the work and results generated, and will allow studies to support the pivotal clinical phases of client drug development.
Catherine Booth, Co-founder and Managing Director of Epistem Contract Research Division commented, “Accreditation strengthens our clinical biomarker capabilities enabling us to support regulatory submissiisonf from partners who use our technology and expertise globally”.
For further information on the Company, please visit www.epistem.co.uk, or contact:
Dr. Kathleen Mackay, 0161 606 7258
Public Relations,07979 577 886